Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

36
Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi

Transcript of Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Page 1: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Pharmacodynamics

HuBio 543

September 6, 2007

Frank F. Vincenzi

Page 2: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Learning Objectives

• Receptors, signal transduction, transmembrane signaling

• Agonist, antagonist, partial agonist, inverse agonist, multiple receptor states

• Intrinsic activity, efficacy, SAR

• Desensitization, up and down regulation

• Quantification of drug receptor interactions and responses

• Potency

• Schild equation and regression

• Competitive and non-competitive antagonism

• Spare receptors

• Kd, EC50, pD2, pA2

Page 3: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Typical concentration-effect curve(plotted arithmetically)

Page 4: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

A slide rule (logarithmic scale)

Page 5: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Typical log concentration-effect curve(graded ‘dose-response’ curve)

Page 6: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Drug (D) - Receptor (R) Interaction

Kd = ([D] * [R]) / [DR] = k2/k1

k1

k2

D + R DR

Kd = dissociation constantk1 = association rate constantk2 = dissociation rate constant

Page 7: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Several ways to express agonist potency &/or apparent affinity of agonists

EC50 (effective concentration, 50%, M)

Kd (apparent dissociation constant, M)

pD2 (negative log of molar concentration (M) of the drug giving a response, which when compared to the maximum, gives a ratio of 2) (i.e., negative log of half maximal concentration)

Page 8: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

The classical concentration-effect relationship and the laws of mass action

Effect = (Effectmax * conc)/(conc + EC50)

In the previous data slide EC50 ~ 3 x 10-9 M

Thus, the apparent Kd of ACh ~ 3 x 10-9 M

IF (NOTE, BIG IF)

EC50 = Kd then

Bound drug = (Bmax * conc)/(conc + Kd)

Page 9: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Binding of a radioligand to tissue samples

Adapted from Schaffhauser et al., 1998

Page 10: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Scatchard analysis of binding of 125iodocyanopindolol to beta-receptors in human heart

Adapted from Heitz et al., 1983

Page 11: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Acetylcholine (ACh): One drug with different affinities for two different receptors

(adapted from Clark, 1933)

Page 12: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

ACh: Different affinities for different receptors

• Muscarinic receptors• EC50 = apparent Kd ~ 3 x 10-8 M, pD2 ~7.5

• Nicotinic receptor• EC50 = apparent Kd ~ 3 x 10-6 M, pD2 ~5.5

• In these experiments, affinity of ACh for muscarinic receptors is apparently ~100 times greater than for nicotinic receptors. ACh is 100 times more potent as a muscarinic agonist than as a nicotinic agonist. So, when injected as a drug, muscarinic effects normally predominate, unless the muscarinic receptors are blocked. (No problem for nerves releasing ACh locally onto nicotinic receptors, however).

Page 13: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Properties of an agonist (e.g., ACh) (on receptors lacking spontaneous activity)

• Accessibility

• Affinity

• Intrinsic activity > 0

Page 14: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Different affinities of related agonist drugs for the same receptor: Different potencies

(adapted from Ariëns et al., 1964)

Page 15: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Properties of an antagonist (on receptors lacking spontaneous activity)

• Accessibility

• Affinity

• Intrinsic activity = 0

Page 16: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Pharmacological antagonism in an intact animal

Page 17: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Properties of a partial agonist (on receptors lacking spontaneous activity)

• Accessibility

• Affinity

• 0 < Intrinsic activity < 1

Page 18: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Theoretical concentration-effect curves for a full and partial agonist of a given receptor

Page 19: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Multiple receptor conformational states:How to understand agonists, partial agonists

and antagonists

Page 20: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Simple case: receptor has little or no spontaneous activity in the absence of added drug

‘inactive’ R ‘active’ R

Page 21: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

An agonist binds more tightly to the ‘active’ state of the receptor:

Equilibrium shifts to the active state

Page 22: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

A competitive antagonist binds equally tightly to the ‘inactive’ and active states of the

receptor: No change in equilibrium

Page 23: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

A partial agonist binds to both the ‘inactive’ and ‘active’ states of the receptor:

Partial shift of equilibrium

Page 24: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Multiple receptor states: How to understand inverse agonists

(in this LESS SIMPLE case, the receptor

has spontaneous (often called constituitive) activity in the absence of added drug)

Page 25: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

The less simple case: Some receptors are ‘active’ even in the absence of added drug

Page 26: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Inverse agonists bind more tightly to the resting state of the spontaneously active receptor: Equilibrium shifts toward the inactive state

Page 27: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Receptor activation by agonists, inverse agonists, etc.

Newman-Tancredi et al., 1997

Page 28: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

How to quantify drug antagonism

• Schild Equation• (C’/C) = 1 + ([I]/Ki)

• Schild plot or Schild regression• log(C’/C - 1) vs. log [I]

• pA2 = -log([I] giving a dose ratio of 2)

• Where [I] = Kd of antagonist at its receptor.

Page 29: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Antagonism of acetylcholine by atropine

Adapted from Altiere et al., 1994

Page 30: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Schild plot of antagonism of acetylcholine by atropine

Adapted from Altiere et al., 1994

Page 31: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Antagonism of acetylcholine by pirenzepine

Adapted from Altiere et al., 1994

Page 32: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Schild plot: Antagonism of acetylcholine by two different antagonists

Adapted from Altiere et al., 1994

-6 -5-10 -9 -8 -70

1

2

3

log [antagonist] (M)

atropine

pirenzepine

Page 33: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

DifferentpA2

values (affinities)for different receptors of some clinically

useful drugs:

The basis of therapeutic selectivity

Page 34: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Evidence for the existence of spare receptors

Page 35: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

How nature achieves neurotransmitter sensitivity without a loss of speed:

Spare receptors:

Page 36: Pharmacodynamics HuBio 543 September 6, 2007 Frank F. Vincenzi.

Drug (D) - Receptor (R) Interaction

Kd = ([D] * [R]) / [DR] = k2/k1

k1

k2

D + R DR

Kd = dissociation constantk1 = association rate constantk2 = dissociation rate constant